Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT ID: NCT07246317
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
188 participants
INTERVENTIONAL
2025-12-15
2032-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
NCT04629846
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
NCT07136974
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
NCT02896855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll 188 subjects, randomly assigned 1:1 to either the QL1706 combination arm or the carboplatin combination arm, stratified by nodal status and hormone receptor status (\<10% vs ≥10%). Both treatment groups will receive four 3-week cycles of assigned therapy followed by surgical resection and response assessment. Postoperative adjuvant treatment will be administered according to investigator discretion and guideline recommendations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QL1706 arm
Trastuzumab, pertuzumab, docetaxel combined with QL1706, q3w, for a total of 4 cycles
QL1706 injection
On Day 1 of each cycle at a dose of 5 mg/kg, IV infusion
Trastuzumab (or biosimilar)
On Day 1 of each cycle; 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks
Pertuzumab (or biosimilar)
On Day 1 of each cycle; 840 mg IV loading dose followed by 420 mg IV every 3 weeks
Docetaxel
On Day 1 of each cycle at a dose of 75 mg/m², IV infusion
Standard therapy arm
Trastuzumab, pertuzumab, docetaxel combined with carboplatin, q3w, for a total of 4 cycles
Trastuzumab (or biosimilar)
On Day 1 of each cycle; 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks
Pertuzumab (or biosimilar)
On Day 1 of each cycle; 840 mg IV loading dose followed by 420 mg IV every 3 weeks
Docetaxel
On Day 1 of each cycle at a dose of 75 mg/m², IV infusion
Carboplatin
On Day 1 of each cycle at a dose of AUC = 4, IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QL1706 injection
On Day 1 of each cycle at a dose of 5 mg/kg, IV infusion
Trastuzumab (or biosimilar)
On Day 1 of each cycle; 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks
Pertuzumab (or biosimilar)
On Day 1 of each cycle; 840 mg IV loading dose followed by 420 mg IV every 3 weeks
Docetaxel
On Day 1 of each cycle at a dose of 75 mg/m², IV infusion
Carboplatin
On Day 1 of each cycle at a dose of AUC = 4, IV infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18-70 years.
3. ECOG PS 0-1; life expectancy \>6 months.
4. Histologically/cytologically confirmed primary breast cancer.
5. Primary tumor \>2cm (by local standard assessment) or node-positive disease.
6. AJCC 8th edition Stage II-IIIC (T2-T4 any N, or any T N1-3 M0) unilateral invasive breast cancer.
7. Confirmed HER2-positive (IHC 3+ or ISH positive). Note: Patients with HER2-negative primary tumor but HER2-positive nodes are eligible.
8. At least one measurable lesion per RECIST 1.1.
9. Agreement to undergo surgery if indicated after neoadjuvant therapy.
10. Willing to provide tumor tissue for biomarker analysis.
11. Adequate organ function:
* ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; HGB ≥90 g/L
* Albumin ≥30 g/L
-. TBIL ≤1.5×ULN; ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases); AKP ≤2.5×ULN
* Creatinine ≤1.5×ULN
* PT/APTT/INR ≤1.5×ULN (or within therapeutic range if on anticoagulants)
12. For women of childbearing potential: negative pregnancy test within 7 days prior to treatment; must not be breastfeeding.
13. Use of highly effective contraception during and for 3 months after treatment.
Exclusion Criteria
2. Inflammatory breast cancer.
3. Other malignancies within 3 years, except: those treated with surgery alone and disease-free for 5 years; cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder cancer \[Ta, Tis, T1\].
4. Prior anti-tumor therapy (chemotherapy, endocrine, anti-HER2) or breast surgery for breast cancer within 3 years (excluding diagnostic biopsy).
5. Major surgery or significant traumatic injury within 28 days before treatment (excluding diagnostic biopsy).
6. Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma in complete remission without intervention in adulthood.
7. Current use of immunosuppressants or systemic corticosteroids (\>10mg/day prednisone equivalent) within 2 weeks prior to enrollment.
8. History of severe hypersensitivity to monoclonal antibodies.
9. Known central nervous system metastases.
10. Poorly controlled concurrent illnesses, including:
* Uncontrolled hypertension (SBP\>150 or DBP\>100 mmHg on medication) or history of hypertensive crisis/encephalopathy.
* History of heart failure or systolic dysfunction (LVEF \<55%).
* Myocardial ischemia/infarction (≥Grade 2), arrhythmias (QTc≥450ms M, ≥470ms F), or CHF (≥NYHA Class II).
* Angina requiring medication; clinically significant valvular disease.
* Active HCV (RNA+), HIV+, syphilis (unless cured), or HBV (HBsAg+ with HBV DNA≥2000 IU/ml or positive qualitative test).
11. Use of Chinese patent medicines with approved anti-tumor indications within 2 weeks prior to treatment.
12. Significant bleeding tendency or clinical bleeding within 3 months; positive fecal occult blood requiring gastroscopy if persistently positive.
13. Tumor invasion or high risk of invasion into major vessels, potentially causing fatal hemorrhage.
14. Pleural, peritoneal, or pericardial effusion requiring drainage (eligible if stable after drainage).
15. Arterial/venous thromboembolic events within 6 months (e.g., CVA, TIA, DVT, PE).
16. Known hereditary or acquired bleeding/thrombotic tendencies (e.g., hemophilia).
17. Severe, non-healing wounds, active ulcers, or untreated fractures.
18. Urinary protein ≥++ confirmed by 24-hour urine protein \>1.0g.
19. Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC \>15×10⁹/L.
20. History of drug abuse or psychiatric disorders.
21. Participation in other anti-tumor drug trials within 4 weeks.
22. Allergy to any study drug or its components.
23. Any condition deemed by the investigator to pose a safety risk or affect study completion.
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU)
Guangzhou, Guangdong, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
Nanyang Central Hospital
Nanyang, Henan, China
The West China Second University Hospital of Sichuan University (WCSUH- SCU)
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QL-BC-QIBA-1005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.